I ntroduction d’androgènes en contraception orale ( Androgen Restored Contraception-ARC)
Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19,...
-
Upload
augustus-wilkerson -
Category
Documents
-
view
221 -
download
0
Transcript of Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19,...
![Page 1: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/1.jpg)
Women’s Health InitiativeAugust 19, 2014
Cleve Ziegler, M.D
![Page 2: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/2.jpg)
CME Speaker: Bayer, Schering-Plough (Merck), Bayer,
Wyeth (Pfizer)
Advisory Board: Bayer, GSK, Schering-Plough (Merck)
![Page 3: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/3.jpg)
Physiology of Menstruation Anthropology of Menstruation Cultural Attitudes Toward Menstruation Update In New Contraceptive Methods Concept of Extended Cycle Contraception
and Menstrual Suppression
![Page 4: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/4.jpg)
![Page 5: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/5.jpg)
![Page 6: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/6.jpg)
Normal Physiological Process Pathological Entity
Ridding the body of toxins
Sign of fertility and femininity
Physiological anemia and reduction in cardiovascular disease
Dysmenorrhea Menorrhagia Endometriosis Ovarian cancer Breast cancer Premenstrual
syndrome Migraine headache Epilepsy
![Page 7: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/7.jpg)
![Page 8: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/8.jpg)
Finer LG. Perspect Sex Reprod Health. 2006; Moreau C. Contraception. 2007. Frost JJ. In Brief. 2008.
UnintendedPregnanciesEach Year
Unintended Pregnancies
Using Contraception
![Page 9: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/9.jpg)
Time Magazine, May 3, 2010.
Nancy Gibbs, Time Executive Editor
“Arriving at a moment of social
and political upheaval,
the Pill became a handy proxy
for wider trends:
the rejection of tradition,
the challenge to institutions,
the redefinition of women’s roles”
![Page 10: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/10.jpg)
![Page 11: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/11.jpg)
![Page 12: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/12.jpg)
Unintended Pregnancy in First Year of Contraceptive Use*
Trussell J. Contraception 2004; 70: 89-96.
85
2 0.3 0.3 0.3 0.6 0.1 0.5
85
15
8 83
0.8 0.1 0.50
10
20
30
40
50
60
70
80
90
No Method Condom COC and POP Patch / Ring DMPA Copper IUD LNG-IUS FemaleSterilization
Perfect Use
Typical Use
85
2 0.3 0.3 0.3 0.6 0.1 0.5
85
15
8 83
0.8 0.1 0.50
10
20
30
40
50
60
70
80
90
No Method Condom COC and POP Patch / Ring DMPA Copper IUD LNG-IUS FemaleSterilization
Perfect Use
Typical Use
Wo
men
wit
h U
nin
ten
ded
Pre
gn
anc
yw
ith
in F
irst
Yea
r o
f U
se
(%)
COC=combined oral contraceptive; POP= progestin only pill; DMPA=depot medroxyprogesterone; LNG-IUS=levonorgestrel releasing intrauterine system
*not head-to-head comparison of contraceptive methods
![Page 13: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/13.jpg)
1
4
6
7
8
10
23
28
38
39
63
0 10 20 30 40 50 60 70
Cervical Cap
Diaphragm
Female Condom
Rhythm
Withdrawal
IUD
Injection
Female Sterilization
Condom
Male Sterilization
Pill
Values in %*Based on Respondents Familiar with Method
Fisher WA et al. JOGC 2004;June :580-590.
![Page 14: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/14.jpg)
DMPA=depot medroxyprogesteroneBack et al. J Obstet Gynaecol Can 2009;31(7):627–640.
Column totals may exceed 100% as women were allowed to choose more than one method.Base: Women aged 15-50 who have had vaginal intercourse in the previous 6 months, n=2,341
0 10 20 30 40 50 60
Condom
Combined oral contraceptive
Male/Female sterilization
Withdrawal
Intrauterine device/system
Rhythm
Natural family planning
Injection:DMPA
% of women
![Page 15: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/15.jpg)
Cultural Preferences Geographic Trends
![Page 16: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/16.jpg)
![Page 17: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/17.jpg)
21/7 Phasic 21/7 Phasic
![Page 18: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/18.jpg)
Estrogen (µg)
160
140
120
80
60
40
20
0
Mestranol
Ethinyl Estradiol
1960 1970 1980 19902000Year of Introduction
Thorneycroft IH. Infert Clin North Am. 2000;11:515-529.
![Page 19: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/19.jpg)
![Page 20: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/20.jpg)
![Page 21: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/21.jpg)
Most serious cardiovascular adverse events associated with
all COCs
Farley et al., Contraception 1996; 57(3)211-30.
Venous thrombo-embolism
StrokeMyocardialinfarction
![Page 22: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/22.jpg)
Dinger Contraception 2007
Non Pregnant Non UsersNon Pregnant Non Users
OC UsersOC Users
Pregnant WomenPregnant Women
![Page 23: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/23.jpg)
BMI: body mass index *Risk estimates based on 115 VTEs in 116,708 WY of exposureDinger, EURAS Study, Presentation EC Prague 2008.
![Page 24: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/24.jpg)
4
171
18 21
53
27
137
111
216
271
0
100
200
300
No Ris
k Fac
tor
Obe
sity
(BM
I 30+
)
Age 4
0+
VTE H
isto
ry**
BMI 3
0+; A
ge 4
0+
BMI 2
5+; H
ist.*
*
BMI3
0+; H
ist.
Age 4
0+; H
ist.
BMI2
5+;A
ge40+
;His
t.
BMI3
0+;A
ge40+
;His
t.
VT
E/1
0,0
00
WY
1 Risk Factor 2 Risk Factors 3 Risk Factors
Impact of Multiple Risk Factors on VTE Risk During OC Use
** Family or personal history of VTEBased on EURAS study results: not yet published
![Page 25: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/25.jpg)
![Page 26: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/26.jpg)
1. Preferential prescribing of new preparations to new users
2. Most VTE in first 6 months, newer users at higher risk
3.Preferential prescribing of new drugs to higher risk patients because of perceived “safety”.
4. Preferential prescribing of drospirenone to hyperandrogenic women who have underlying vascular disease
![Page 27: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/27.jpg)
![Page 28: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/28.jpg)
1 ring per cycle Regimen:
◦3 weeks of ring-use◦1 ring-free week
Daily release:◦15 µg ethinylestradiol◦120 µg etonogestrel
![Page 29: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/29.jpg)
-500
0
500
1000
1500
2000
0 5 10 15 20
Time after insertion (days)
Eto
noge
stre
l (pg
/mL)
0
10
20
30
40
50
60
Eth
inyl
estr
adio
l (pg
/mL)
EtonogestrelEthinylestradiol
Css OC
Css OC
Pharmacokinetic profilePharmacokinetic profile NuvaRing and 30 EE/150 DSG COCNuvaRing and 30 EE/150 DSG COC
Timmer & Mulders, Clin Pharmacokinet, 2000;39:233–42
![Page 30: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/30.jpg)
![Page 31: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/31.jpg)
![Page 32: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/32.jpg)
D’Arcangues et a., Contraception. 2007; 75: S2-S7
Prevalence of IUD use in women aged 15-49, married or in union (2005)
![Page 33: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/33.jpg)
Intrauterine system (IUS) Releases up to 20 μg/day
of levonorgestrel (progestin)
No estrogen 5 years of treatment
Indications Contraception
![Page 34: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/34.jpg)
Mirena provides contraception througha combination of 3 main actions:
Minor effect
on ovarian function
2- Inhibition of sperm function
1- Thickening of cervical mucus
3- Prevention of endometrial growth
![Page 35: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/35.jpg)
Normal menstrual cycle
Days of cycle
Menstrual cycle in awoman with Mirena
Endometrium in resting stateResulting in scanty bleeding
![Page 36: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/36.jpg)
![Page 37: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/37.jpg)
![Page 38: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/38.jpg)
![Page 39: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/39.jpg)
![Page 40: Update In Contraception 2014: New Options, New Controversies Women’s Health Initiative August 19, 2014 Cleve Ziegler, M.D.](https://reader036.fdocuments.us/reader036/viewer/2022062300/56649d1a5503460f949efb31/html5/thumbnails/40.jpg)
1. Use 2nd generation pill with lowest estrogen dose as first choice
2.If adverse effects occur, switch to 3rd or 4th generation pill.
3.Patients at high risk for VTE should use progestin only pill, DMPA, or IUS.
4.Use 2nd generation pill in older women